MXPA05001623A - Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo. - Google Patents

Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo.

Info

Publication number
MXPA05001623A
MXPA05001623A MXPA05001623A MXPA05001623A MXPA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A
Authority
MX
Mexico
Prior art keywords
heart failure
pharmaceutically acceptable
benzazepine
acceptable salt
group
Prior art date
Application number
MXPA05001623A
Other languages
English (en)
Spanish (es)
Inventor
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05001623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MXPA05001623A publication Critical patent/MXPA05001623A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05001623A 2003-02-24 2004-02-23 Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo. MXPA05001623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (1)

Publication Number Publication Date
MXPA05001623A true MXPA05001623A (es) 2005-04-25

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05001623A MXPA05001623A (es) 2003-02-24 2004-02-23 Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo.

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP1596868B1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
PT1968990E (pt) 2005-12-27 2015-03-16 Otsuka Pharma Co Ltd Composto de benzoazepina solúvel em água e a sua composição farmacêutica
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
AU2008254273B2 (en) * 2007-05-15 2013-03-28 Otsuka Pharmaceutical Co., Ltd. Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
JP2013526388A (ja) 2010-05-25 2013-06-24 イエナバルブ テクノロジー インク 人工心臓弁、及び人工心臓弁とステントを備える経カテーテル搬送体内プロテーゼ
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US12121461B2 (en) 2015-03-20 2024-10-22 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
WO2016177562A1 (en) 2015-05-01 2016-11-10 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
CN120152682A (zh) 2022-11-09 2025-06-13 耶拿阀门科技公司 用于顺序地部署可扩张植入物的导管系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
TW249201B (enExample) 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な5−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) * 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
ATE341342T1 (de) 2000-01-26 2006-10-15 Astellas Pharma Inc Ace inhibitor-vasopressin antagonist kombinationen
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
CA2357833C (en) 2000-10-04 2005-11-15 Warner-Lambert Company Treatment of pulmonary hypertension using vasopressin antagonist
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
PL373432A1 (en) 2005-08-22
KR100706727B1 (ko) 2007-04-12
EP1596868B1 (en) 2008-10-22
DK1596868T3 (da) 2008-12-08
KR20050105972A (ko) 2005-11-08
RU2005102110A (ru) 2005-09-20
BRPI0405657A (pt) 2005-07-19
ATE411803T1 (de) 2008-11-15
CY1108583T1 (el) 2014-04-09
NO20050569D0 (no) 2005-02-02
US20050187210A1 (en) 2005-08-25
EP1596868A1 (en) 2005-11-23
SI1596868T1 (sl) 2008-12-31
AU2004212842A1 (en) 2004-09-02
JP2006518731A (ja) 2006-08-17
AU2009201109A1 (en) 2009-04-09
MY143740A (en) 2011-07-15
CN100577171C (zh) 2010-01-06
ES2315640T3 (es) 2009-04-01
DE602004017283D1 (de) 2008-12-04
CA2493475A1 (en) 2004-09-02
TWI322689B (en) 2010-04-01
PL218069B1 (pl) 2014-10-31
PT1596868E (pt) 2009-01-14
US7423032B2 (en) 2008-09-09
EP2000142A1 (en) 2008-12-10
RU2008133654A (ru) 2010-02-20
JP4771937B2 (ja) 2011-09-14
CN1700919A (zh) 2005-11-23
JP2011148806A (ja) 2011-08-04
AU2004212842B9 (en) 2009-03-05
NO335369B1 (no) 2014-12-01
RU2346689C2 (ru) 2009-02-20
AR043259A1 (es) 2005-07-20
AU2004212842B2 (en) 2009-01-08
WO2004073716A1 (en) 2004-09-02
EP1596868A4 (en) 2006-03-29
TW200418489A (en) 2004-10-01
US20080214523A1 (en) 2008-09-04
PL404315A1 (pl) 2013-08-05
US7749993B2 (en) 2010-07-06
NO20050569L (no) 2005-11-22
HK1084037A1 (zh) 2006-07-21

Similar Documents

Publication Publication Date Title
US7749993B2 (en) Method for treating severe heart failure and medicament therefor
WO2008025781A1 (en) Bifeprunox doses for treating schizophrenia
JP6328856B2 (ja) 収縮力低下随伴性排尿筋過活動改善剤
HK1084037B (en) Medicament for treating severe heart failure
US20250186405A1 (en) Compound For Use In Treating Narcolepsy
JP3002766B2 (ja) 脳浮腫治療剤
JP3758700B2 (ja) 徐脈性不整脈治療剤
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
JPH0776584A (ja) 内皮細胞障害抑制剤
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
JPH06211657A (ja) 尿酸排泄剤
HK1078012A (en) Therapeutic agent for overactive bladder
HK1133190A (en) Bifeprunox doses for treating schizophrenia
MXPA05011808A (en) Uses of ion channel modulating compounds
CN103463015A (zh) 咪达那新在制备治疗高血压的药物中的应用

Legal Events

Date Code Title Description
FG Grant or registration